Invesco Ltd. Sells 1,323,514 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Invesco Ltd. cut its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,296,255 shares of the biotechnology company's stock after selling 1,323,514 shares during the period. Invesco Ltd. owned approximately 4.78% of ADMA Biologics worth $193,731,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics during the third quarter worth about $61,858,000. Raymond James Financial Inc. bought a new position in ADMA Biologics in the 4th quarter worth approximately $19,076,000. EWG Elevate Inc. bought a new position in ADMA Biologics in the 4th quarter valued at about $480,000. Allspring Global Investments Holdings LLC raised its holdings in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Finally, Veracity Capital LLC boosted its stake in ADMA Biologics by 117.0% during the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after buying an additional 25,030 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Performance

ADMA traded down $0.07 during trading on Thursday, reaching $21.17. 1,018,230 shares of the company's stock were exchanged, compared to its average volume of 3,598,580. The company has a market capitalization of $5.00 billion, a P/E ratio of 75.43 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $23.64. The business has a 50 day moving average price of $18.05 and a 200 day moving average price of $18.21.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.